Ftse Mib
35.398,82
-0,03%
DAX
18.704,42
-0,11%
S&P 500
5.303,27
0,12%
NASDAQ
16.685,97
-0,07%
Bitcoin
66.248,73
-1,03%

Quotazioni in diretta

Non abbiamo trovato risultati per:
Assicurati di aver scritto correttamente o prova ad allargare la ricerca.

Più Attivi

Toplist

Sembra che tu non sia connesso.
Clicca il pulsante qui sotto per accedere e visualizzare la tua cronologia recente.

Registrati

Sei già registrato? Accedi

Pepperstone

Inizia Ora

Pepperstone
Home Investire Azioni U.S.A. NASDAQ Cyteir Therapeutics Inc (CYT) Cyteir Therapeutics Inc (CYT) Notizie

CYT

Cyteir Therapeutics (CYT)

HOME News News di Agenzia

News di Agenzia

Da:
 Ti mostriamo gli articoli più rilevanti per la tua ricerca:NASDAQ:CYT
DataOraFonteTitoloSimboloCompagnia
07/03/202422:31Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:CYTCyteir Therapeutics Inc
07/03/202422:30Business WireCyteir Announces Timeline for Voluntarily Delisting from NasdaqNASDAQ:CYTCyteir Therapeutics Inc
06/03/202400:11Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:CYTCyteir Therapeutics Inc
15/02/202401:36Edgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]NASDAQ:CYTCyteir Therapeutics Inc
06/11/202322:01Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:CYTCyteir Therapeutics Inc
12/10/202322:14Edgar (US Regulatory)Form DEFM14A - Definitive proxy statement relating to merger or acquisitionNASDAQ:CYTCyteir Therapeutics Inc
12/10/202313:52Edgar (US Regulatory)Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) materialNASDAQ:CYTCyteir Therapeutics Inc
12/10/202313:30Business WireOngoing Results From a Dose Expansion Cohort of CYT-0851 in Combination With Capecitabine in Advanced Platinum-Resistant Ovarian Cancer Show Promising Clinical Activity and Generally Well Tolerated Safety ProfileNASDAQ:CYTCyteir Therapeutics Inc
02/10/202322:44Edgar (US Regulatory)Form PREM14A - Preliminary proxy statements relating to merger or acquisitionNASDAQ:CYTCyteir Therapeutics Inc
30/06/202323:29Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:CYTCyteir Therapeutics Inc
30/06/202316:38Edgar (US Regulatory)Additional Proxy Soliciting Materials (definitive) (defa14a)NASDAQ:CYTCyteir Therapeutics Inc
30/06/202316:22Edgar (US Regulatory)Current Report Filing (8-k)NASDAQ:CYTCyteir Therapeutics Inc
30/06/202314:00Business WireCyteir Therapeutics Announces Discontinuation of CYT-0851 Development Program and Planned Liquidation and DissolutionNASDAQ:CYTCyteir Therapeutics Inc
29/06/202300:03Edgar (US Regulatory)Report of Proposed Sale of Securities (144)NASDAQ:CYTCyteir Therapeutics Inc
20/06/202323:54Edgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:CYTCyteir Therapeutics Inc
03/06/202315:00Business WirePreliminary Ongoing Results with CYT-0851 in Combination with Capecitabine or Gemcitabine in Advanced Solid Tumors Show Early Clinical Activity and Generally Well Tolerated Safety ProfileNASDAQ:CYTCyteir Therapeutics Inc
10/05/202322:01Business WireCyteir Therapeutics Reports First Quarter 2023 Financial Results and Operational HighlightsNASDAQ:CYTCyteir Therapeutics Inc
27/04/202322:23Edgar (US Regulatory)Annual Report to Security Holders (ars)NASDAQ:CYTCyteir Therapeutics Inc
27/04/202322:10Edgar (US Regulatory)Proxy Statement (definitive) (def 14a)NASDAQ:CYTCyteir Therapeutics Inc
23/03/202321:24Edgar (US Regulatory)Prospectus Filed Pursuant to Rule 424(b)(3) (424b3)NASDAQ:CYTCyteir Therapeutics Inc
23/03/202321:17Edgar (US Regulatory)Annual Report (10-k)NASDAQ:CYTCyteir Therapeutics Inc
23/03/202321:01Business WireCyteir Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Operational HighlightsNASDAQ:CYTCyteir Therapeutics Inc
14/02/202320:43Edgar (US Regulatory)Amended Statement of Ownership (sc 13g/a)NASDAQ:CYTCyteir Therapeutics Inc
06/02/202314:15Business WireCyteir Therapeutics Promotes David Gaiero to Chief Financial OfficerNASDAQ:CYTCyteir Therapeutics Inc
03/02/202322:07Edgar (US Regulatory)Amended Current Report Filing (8-k/a)NASDAQ:CYTCyteir Therapeutics Inc
19/01/202322:30Business WireCyteir Therapeutics Announces Prioritization of CYT-0851 Development and Extended Cash RunwayNASDAQ:CYTCyteir Therapeutics Inc
07/11/202222:10Edgar (US Regulatory)Quarterly Report (10-q)NASDAQ:CYTCyteir Therapeutics Inc
07/11/202222:01Business WireCyteir Therapeutics Reports Third Quarter 2022 Financial Results and Operational HighlightsNASDAQ:CYTCyteir Therapeutics Inc
12/10/202214:00Business WireCyteir Therapeutics Presents Poster on the Identification of Mechanism of Action of CYT-0851 at the 34th Annual EORTC-NCI-AACR SymposiumNASDAQ:CYTCyteir Therapeutics Inc
31/08/202213:30Business WireCyteir Therapeutics to Participate in the Morgan Stanley 20th Annual Global Healthcare ConferenceNASDAQ:CYTCyteir Therapeutics Inc
 Ti mostriamo gli articoli più rilevanti per la tua ricerca:NASDAQ:CYT

La tua Cronologia

TSX
NUAG
New Pacific Metals
COIN
PNDXETH
Pond0x
LSE
DISW
Lyxor Wld Con
TG
D69
DS Norden
NASDAQ
PGEIX
TG
3RCA
RingCentral
TSXV
SMS.H
USOTC
GTMEY
Globe Telecom (PK)
USOTC
OTCNS
Otis Collection (GM)
EU
NEIAE
Nexity 2.053% 10nov2023
COIN
SPAREUR
NASDAQ
FSRSRX
Sabrient Dividend Portfo...
BITMOT
996040
World Bank Sustainable T...
NASDAQI
MTVRKRWN
Global Metaverse Index N...
KUCN
STOREETH
Bit Store Coin
BIT
UB352J
UniCredit Bank
Delayed Upgrade Clock
Per accedere al tempo reale push di Borsa è necessario registrarsi.

Il sito ADVFN Italia è stato realizzato ed è gestito da PRODESFIN su licenza di ADVFN PLC.

PER CONTATTI E PUBBLICITA' CLICCA QUI

Accedendo ai servizi offerti da ADVFN, ne si accettano le condizioni generali Termini & Condizioni

ADVFN Network